Biotechnology Archives

This explosive, high upside sector is running higher. Do you own it?

Space stocks are rebounding after a sharp correction. Here are four leading space stocks and one ETF positioned to benefit from the industry's growth.

By Brian Hunt | August 18, 2026

Read this issue

Stocks for investing in “the next big AI trade”

Natera jumps 21% to an all-time high. AI agents are set to make humans a rounding error on the internet. And FSR stocks say the American consumer is thriving.

By Brian Hunt | August 10, 2026

Read this issue

Four actionable stock ideas from a legendary investor

Druckenmiller is loading up on biotech. Eaton's earnings confirm the power grid boom. And WSM's new high says the American consumer is alive and thriving.

By Brian Hunt | August 4, 2026

Read this issue

These unique stocks can earn you big returns over the next four years

Discover why Made in America manufacturing, biotech innovation, and natural gas infrastructure could power long-term investment returns.

By Brian Hunt | July 9, 2026

Read this issue

Three stocks to invest in an industry guaranteed to soar in size

AI's energy hunger is fueling a bull market in battery storage and fuel cells — while ophthalmology and genomics hit new highs. Here are the stocks positioned to win across all three trends.

By Brian Hunt | June 29, 2026

Read this issue

AI Drug Discovery Stocks: Follow the Money, Not the Cure

Isomorphic Labs has the best AI drug-design tool in the world. But it’s private – you can’t buy it. Here are 6 public AI drug discovery stocks to trade the same thesis.

By Jonathan Rose | June 25, 2026

Read this issue

Biotechnology

Article Date Range

Author

Categories

This explosive, high upside sector is running higher. Do you own it?

Stocks for investing in “the next big AI trade”

Four actionable stock ideas from a legendary investor

These unique stocks can earn you big returns over the next four years

Three stocks to invest in an industry guaranteed to soar in size

AI Drug Discovery Stocks: Follow the Money, Not the Cure